Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BCRX
- Price
- 7.40
- Stock movement up
- +0.18 (2.49%)
- Company name
- BioCryst Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.53B
- Ent value
- 2.40B
- Price/Sales
- 3.72
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 3.73%
- 1 year return
- 60.52%
- 3 year return
- -12.19%
- 5 year return
- 21.80%
- 10 year return
- -2.72%
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BCRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.72 |
| Price to Book | - |
| EV to Sales | 5.81 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 207.13M |
| EPS (TTM) | -0.60 |
| FCF per share (TTM) | -0.28 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 412.58M |
| Gross profit (TTM) | 403.97M |
| Operating income (TTM) | -40.58M |
| Net income (TTM) | -123.82M |
| EPS (TTM) | -0.60 |
| EPS (1y forward) | -0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 97.91% |
| Operating margin (TTM) | -9.84% |
| Profit margin (TTM) | -30.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 96.84M |
| Net receivables | 72.46M |
| Total current assets | 427.13M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 491.25M |
| Accounts payable | 13.48M |
| Short/Current long term debt | 809.14M |
| Total current liabilities | 153.57M |
| Total liabilities | 959.82M |
| Shareholder's equity | -468.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -56.13M |
| Capital expenditures (TTM) | 1.00M |
| Free cash flow (TTM) | -57.13M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -25.20% |
| Return on Invested Capital | -37.47% |
| Cash Return on Invested Capital | -17.29% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.17 |
| Daily high | 7.51 |
| Daily low | 7.14 |
| Daily Volume | 3.35M |
| All-time high | 33.13 |
| 1y analyst estimate | 14.82 |
| Beta | 1.89 |
| EPS (TTM) | -0.60 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| BCRX | S&P500 | |
| Current price drop from All-time high | -77.66% | -14.12% |
| Highest price drop | -97.74% | -56.47% |
| Date of highest drop | 3 Jul 2002 | 9 Mar 2009 |
| Avg drop from high | -69.50% | -11.07% |
| Avg time to new high | 261 days | 12 days |
| Max time to new high | 6197 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.53B
Marketcap category
Small-cap
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Employees
536
Website
Investor relations
SEC filings
CEO
Jon P. Stonehouse
Country
USA
City
Durham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page